Galecto Stock Price

-0.07 (-1.61%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Galecto Inc GLTO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.07 -1.61% 4.29 00:00:05
Open Price Low Price High Price Close Price Prev Close
4.32 4.27 4.35 4.29 4.36
Bid Price Ask Price Spread News
4.10 5.13 1.03 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
283 33,080 $ 4.30 $ 142,144 - 4.03 - 17.99
Last Trade Time Type Quantity Stock Price Currency
19:43:41 1 $ 4.71 USD


Draw Mode:

Galecto Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 108.37M 25.26M 19.59M $ - $ - -7.86 -0.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 201.00k 0.30%

more financials information »

Galecto News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GLTO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.484.554.14124.38106,717-0.19-4.24%
1 Month5.,287-0.74-14.71%
3 Months5.5116.414.035.911,296,315-1.22-22.14%
6 Months12.7316.414.035.97613,514-8.44-66.3%
1 Year15.7717.994.036.22426,316-11.48-72.8%
3 Years15.7717.994.036.22426,316-11.48-72.8%
5 Years15.7717.994.036.22426,316-11.48-72.8%

Galecto Description

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210801 07:05:19